The Wegovy weight loss timeline: what actually happens and when

The first few weeks: your body is adjusting, not transforming yet

Picture this: you've just had your first Wegovy pen delivered, tucked it in the fridge, and done your first injection on a Tuesday morning before work. The dose is 0.25mg. It feels anticlimactic. You're not sure anything is happening.

That's normal — and intentional. The 0.25mg starting dose exists purely to help your digestive system get used to semaglutide. It isn't the dose that drives meaningful weight loss; it's the biological handshake before the real conversation starts. Most people notice some mild nausea or a slight reduction in appetite in these first weeks, but the scales often don't move much. Expecting dramatic early results here sets people up for disappointment.

What is happening beneath the surface: semaglutide is beginning to slow gastric emptying and interact with the appetite-signalling pathways in your brain. The groundwork is being laid. Give it time rather than scrutiny.

The semaglutide overview on our site explains the mechanism in more depth if you want the science behind what that first pen is doing.

Months one to three: the escalation phase, when most people notice a shift

By the time you've moved through the 0.5mg and 1mg steps (still well below the maintenance dose) appetite suppression tends to become genuinely noticeable. Portions feel satisfying sooner. The pull toward snacking fades a little. For many people, this is the first moment the medicine feels real.

Weight loss in this phase is modest by the numbers but meaningful in experience. Some people lose three to five kilograms; others less. A lot depends on starting weight, dietary changes and activity. The full picture of what affects Wegovy weight loss results covers those variables in detail, and if you want to understand how semaglutide drives weight loss at a biological level, that's a useful companion read.

Nausea is most likely here, particularly around each dose step-up. It usually improves within a week or two. Eating smaller meals, avoiding very fatty or rich foods, and staying hydrated all help. If symptoms feel unmanageable, that's a conversation for your prescriber, not a reason to quietly stop.

The dose schedule continues: 1.7mg comes next, then 2.4mg (the standard maintenance dose) typically reached around week 17. From April 2026, a 7.2mg dose has also been approved by the MHRA for eligible patients, though that's a longer-term discussion with your clinician.

Months three to twelve: the period where the timeline really earns its reputation

This is the phase that drives the headline trial results. Once people reach and stabilise at their maintenance dose, weight loss typically accelerates and then settles into a steadier pace. If you want a clear picture of how long Wegovy takes to produce results at each stage, our Wegovy timeline walks through the full progression week by week.

In the STEP 1 trial (68 weeks, 1,961 adults with obesity or overweight and at least one weight-related condition) participants on semaglutide 2.4mg lost an average of around 15% of their body weight, compared with about 2.4% on placebo, as published in the New England Journal of Medicine. That loss didn't happen in one burst. The curves show steady decline through month twelve, with a plateau beginning to form toward the end of the study period.

Real-world timelines vary more than trial averages suggest. Stress, sleep, what else is going on medically, how consistently you take the injection, all of it shapes the curve. The average is a benchmark, not a guarantee.

If you're curious about the broader context of how Wegovy sits among available weight-loss medicines, that's worth reading alongside the trial data.

Beyond twelve months: what happens when weight loss slows or stops

A plateau isn't failure. It's biology. By around month twelve to eighteen, many people find their weight stabilises, sometimes before they've reached their personal goal. This is where honest conversations with your prescriber matter most.

A few things worth knowing. First, the 2-year treatment limit under NHS NICE guidance (TA875) for semaglutide reflects the trial data available at the time of appraisal; private treatment is a separate clinical conversation. Second, weight can return when treatment stops, which is why ongoing clinical review (and lifestyle foundations built during treatment) carries real long-term weight. Third, if less than 5% of starting body weight has been lost after six months at the maintenance dose, NICE guidance suggests reviewing whether continuing is appropriate.

The NICE technology appraisal for semaglutide (TA875) sets out the clinical criteria in full. For a broader look at what weight management with GLP-1 medicines involves over time, the weight loss treatment overview is a useful next read.

If you'd like to talk through whether Wegovy fits your situation, check your eligibility with our prescribers, a consultation is free and reviewed the same day by a real clinician, not automated software.